Fri, February 23, 2024
Thu, February 22, 2024
Wed, February 21, 2024
Tue, February 20, 2024
Mon, February 19, 2024
Fri, February 16, 2024

Charles Duncan Maintained (AXSM) at Buy with Decreased Target to $103 on, Feb 21st, 2024

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-103-on-feb-21st-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Charles Duncan of Cantor Fitzgerald, Maintained "Axsome Therapeutics, Inc." (AXSM) at Buy with Decreased Target from $108 to $103 on, Feb 21st, 2024.

Charles has made no other calls on AXSM in the last 4 months.



There are 5 other peers that have a rating on AXSM. Out of the 5 peers that are also analyzing AXSM, 0 agree with Charles's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Charles


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $112 on, Friday, February 16th, 2024
  • Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $111 on, Tuesday, February 6th, 2024
  • David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $113 on, Tuesday, January 16th, 2024
  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Tuesday, December 26th, 2023
  • David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $125 on, Wednesday, December 13th, 2023